A 28-year-old male presents with mild nodular acne, recurrently affecting the jaw region. The lesions are few in number but consistently nodular. He also exhibits post-inflammatory hyperpigmentation. Currently, his treatment regimen includes: Tablet Doxycycline 100 mg once daily, administered in the morning, for the past 6-7 weeks. Gel Benzoyl Peroxide 5%, applied in the morning, for the past 6-7 weeks. Gel Adapalene 0.1%, applied nightly before sleep, also for the past 6-7 weeks. Please evaluate the current treatment plan and formulate an optimized treatment strategy for this patient, suggesting any necessary modifications.

Reading File
Finding Sources
Finding Sources
Searching PubMed

acne vulgaris treatment guideline

Searching the Web

nodular acne treatment doxycycline benzoyl peroxide adapalene not improving guideline

Reading File
Finding Sources
Finding Sources
Reading File

Assessment of the Current Regimen

The three agents chosen are appropriate first-line, guideline-concordant therapy for inflammatory acne:
  • Adapalene 0.1% (topical retinoid) - comedolytic, anti-inflammatory, and also accelerates resolution of post-inflammatory hyperpigmentation (PIH).
  • Benzoyl peroxide 5% (BPO) - bactericidal against C. acnes, and critically, co-prescribing it with an oral antibiotic is a "good practice statement" in the 2024 AAD guideline because it reduces the risk of antibiotic resistance.
  • Doxycycline 100 mg OD - appropriate for inflammatory/nodular disease; never used as monotherapy here, which is correct.
Splitting the topicals (BPO in the morning, adapalene at night) is also sound practice, since combining them in the same application can reduce retinoid stability and increase irritation - Dermatology, 2-Vol Set, 5e, p. 728-729.
So the backbone of the regimen is correct. The gaps are in duration planning, photoprotection, PIH-directed care, and lesion-specific management of the nodules, not in the drug choices themselves.

Gaps to Address

1. No sun protection prescribed. Doxycycline is a recognized photosensitizer (Fitzpatrick's Dermatology; Goldman-Cecil Medicine), and UV exposure will also worsen his existing PIH. A broad-spectrum, non-comedogenic sunscreen (SPF 30-50) every morning is a necessary addition, not optional - it protects against both problems simultaneously.
2. Antibiotic duration not yet capped. He's at 6-7 weeks. Guidelines (AAD 2024, NICE) recommend limiting oral antibiotic courses to 3 months maximum, with a planned transition to topical-only maintenance once nodules/inflammatory lesions clear, to limit resistance. Set a hard stop date now rather than continuing indefinitely.
3. Nodules are being treated systemically only. For a patient with "few but consistently nodular" lesions, intralesional triamcinolone acetonide (2.5-5 mg/mL) injected directly into individual nodules is a highly effective adjunct - it flattens lesions within days and meaningfully reduces the risk of scarring and further PIH, which systemic/topical therapy alone won't achieve as quickly for an established nodule.
4. PIH is not being directly targeted. Right now PIH is only being addressed indirectly (adapalene helps fade it over time). Once active inflammation is reduced, consider adding azelaic acid 15-20% (dual-purpose - antimicrobial/comedolytic and a depigmenting agent shown effective for PIH and melasma - Dermatology, 2-Vol Set 5e) or niacinamide/topical vitamin C as tolerated. Avoid adding a second irritant (e.g., hydroquinone) simultaneously with adapalene+BPO until the skin barrier tolerates it, to prevent excess irritation-driven pigmentation.
5. Administration counseling.
  • Take doxycycline with a full glass of water, remain upright for 30 minutes afterward (esophagitis risk), and separate from dairy, calcium, iron, or antacids by ~2 hours (chelation reduces absorption).
  • Warn explicitly about photosensitivity and reinforce daily sunscreen.
  • If dryness/irritation from adapalene+BPO develops, use a non-comedogenic moisturizer and consider short-contact or alternate-day retinoid dosing rather than discontinuing.

Optimized Plan

ElementRecommendation
Adapalene 0.1% gelContinue nightly - also helps fade PIH
BPO 5% gelContinue mornings
Doxycycline 100 mgContinue, but plan to stop by ~12 weeks total (currently at week 6-7); document response at each visit
SunscreenAdd now - broad-spectrum, non-comedogenic, SPF 30+, daily
NodulesConsider intralesional triamcinolone for the few nodular lesions to hasten resolution and limit scarring/PIH
PIHReinforce photoprotection + retinoid; add azelaic acid once acne is more controlled and tolerability allows
Adherence counselingConfirm correct application technique (entire acne-prone area, not spot treatment), avoid harsh scrubs/additional actives

Follow-Up / Escalation Criteria

Reassess at 12 weeks (full antibiotic course):
  • Good response → taper/stop doxycycline, continue adapalene + BPO (or a fixed-combination product) indefinitely as maintenance, since relapse is common if topicals are stopped too.
  • Inadequate response, new nodules, or scarring → this meets guideline criteria for escalation to oral isotretinoin, which the AAD 2024 guideline strongly recommends for acne that is "severe, causing psychosocial burden or scarring, or failing standard oral or topical therapy." Baseline labs (LFTs, lipids) would be obtained before starting.
This assessment is based on current dermatology texts (Dermatology, 2-Volume Set, 5th ed.; Fitzpatrick's Dermatology) and the 2024 AAD acne guideline (PMID 38300170), which remains the most current systematic-review-backed guidance and does not contradict the plan above - it in fact reinforces the antibiotic-stewardship and combination-therapy elements included here.

Find latest 2024-2025 acne management guidelines and protocols

Searching PubMed

acne vulgaris AND "guideline"[pt]

Searching PubMed

acne vulgaris treatment consensus 2025

Searching the Web

latest acne management guidelines 2024 2025 AAD European consensus

Searching the Web

2025 acne treatment guideline update JAAD EADV

Searching the Web

benzoyl peroxide benzene contamination FDA 2024 2025 acne products citizen petition

Reading Web Page

https://www.empr.com/home/news/aad-issues-updated-clinical-p…

2024-2025 Acne Management Guidelines and Protocols

1. The flagship update: AAD 2024 Guidelines of Care for Acne Vulgaris

The 2024 American Academy of Dermatology guideline (Reynolds et al., JAAD, published online Jan 30, 2024) replaced the 2016 AAD guideline and remains the most heavily cited, systematic-review-backed document. It issued 18 evidence-based recommendations and 5 good practice statements:
Strong recommendations (topical): benzoyl peroxide, topical retinoids (adapalene, tretinoin, tazarotene, trifarotene), topical antibiotics (not as monotherapy), and fixed-dose combination products (better adherence, sometimes cheaper than separate components).
Strong recommendations (systemic): oral doxycycline; isotretinoin for severe acne, acne causing psychosocial burden or scarring, or acne failing standard therapy.
Conditional recommendations: minocycline, sarecycline, topical clascoterone, salicylic acid, azelaic acid, combined oral contraceptives, spironolactone.
Good practice statements:
  • Limit systemic antibiotic duration to reduce resistance.
  • Always pair systemic antibiotics with benzoyl peroxide/other topicals.
  • Use intralesional corticosteroids as adjuvant therapy for larger papules/nodules, especially in patients at risk of scarring.
  • Mandatory pregnancy prevention for isotretinoin in patients of childbearing potential; LFTs/lipids monitoring reasonable (CBC not required in healthy patients).
  • The guideline recommends against adding pneumatic broadband light to adapalene 0.3% gel (no added benefit shown).

2. Antibiotic stewardship consensus (2025)

A 2025 modified-Delphi expert panel, Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management, reinforced and operationalized the AAD antibiotic guidance: oral antibiotics should be used for the shortest effective duration, ideally no more than 3-4 months, always combined with benzoyl peroxide, with a defined plan at initiation for tapering to topical-only maintenance.

3. Regional/national updates (2024-2025)

  • UK (NICE/BAD): The NICE guideline itself dates to Dec 2023, but a 2024 review, "What's New After NICE Acne Guidelines" (Layton et al., Dermatology and Therapy), clarified practical gaps - e.g., preferred first-line combination of topical adapalene + BPO, with oral lymecycline/doxycycline added for moderate-severe disease, antibiotics capped at 3-6 months.
  • Canada: Update to Acne Vulgaris Treatment for Canadian Practice (Keow et al., Canadian Family Physician, 2025) - adapted the AAD framework for primary care, emphasizing combination topical therapy first, isotretinoin thresholds, and hormonal therapy options for women.
  • India: PRACT-India: Practical Recommendations on Acne Care and Medical Treatment - a 2025 modified-Delphi consensus tailored to Indian skin types, climate, and drug availability.
  • Switzerland: Updated Swiss Practice Recommendations for the Treatment of Acne (2025) - aligns with AAD/European approaches on combination therapy and antibiotic duration.
  • Malaysia: 2026 advisory bridging local guideline gaps specifically around trifarotene for facial and truncal acne.
  • Europe: The European Dermatology Forum released a fully updated Treatment of Acne guideline in March 2026 (superseding the older 2012 European S3 guideline), the newest major regional document in this space.

4. Isotretinoin-specific consensus

ERAISE ACNE (Expert Consensus on the Rational Approach to Isotretinoin Usage) strongly supports first-line isotretinoin in pediatric/adolescent patients (12-18 yrs) with severe conglobate acne, severe nodulocystic acne (>3 nodules/cysts), or severe papulopustular acne with scarring/psychosocial impact - a more permissive stance than older guidelines that reserved isotretinoin strictly for treatment failures.

5. Dermocosmetics/adjunct skincare consensus

An international expert consensus (Thiboutot et al., JEADV 2025) formally incorporated dermocosmetics (gentle cleansers, moisturizers, sunscreens, barrier-repair ingredients) into standard acne care protocols, and a related U.S. algorithm ("Acneceuticals" algorithm, Baldwin et al., JDD 2025) gives a structured approach to layering OTC actives with prescription therapy to improve tolerability and adherence.

6. Important safety development: benzoyl peroxide and benzene

This is the most clinically relevant new safety issue since 2024 and directly affects prescribing of BPO-based regimens:
  • March 2024: Valisure filed an FDA citizen petition reporting that BPO can degrade into benzene (a carcinogen) under high heat/storage conditions, prompting over 35 class-action lawsuits.
  • March 2025: FDA tested 95 BPO products; more than 90% showed undetectable or extremely low benzene levels, but 6 products were voluntarily recalled after showing elevated levels (list includes La Roche-Posay Effaclar Duo, Proactiv Emergency Blemish Relief Cream 5% BPO, SLMD Benzoyl Peroxide Acne Lotion, Walgreens products).
  • FDA's position: even with decades of daily use, cancer risk from benzene in these products is considered very low, and it has not advised patients to stop using BPO.
  • Practical takeaway for prescribing: advise patients to store BPO products at room temperature, away from heat/sun, and avoid stockpiling long-expired product, rather than discontinuing an effective, guideline-endorsed therapy.

7. Newer treatment modalities gaining guideline attention

  • A 2025 JAAD clinical review formally evaluated light and laser-based therapies (photodynamic therapy, pulsed dye laser, 1726 nm lasers targeting sebaceous glands) as emerging adjuncts, particularly for patients wanting to minimize systemic antibiotic/isotretinoin exposure.
  • Continued interest in topical spironolactone for acne (2026 meta-analysis) and microbiome-targeted therapy as investigational future directions, not yet incorporated into mainstream guidelines.

How this updates the plan for your earlier patient

Nothing here changes the core AAD-2024-based regimen already recommended (retinoid + BPO + short-course doxycycline + intralesional triamcinolone for nodules + antibiotic stewardship). Two practical refinements from these 2024-2025 updates:
  1. Reinforce the 3-4 month hard cap on doxycycline per the 2025 antibiotic stewardship consensus.
  2. Counsel him to store the BPO gel away from heat and direct sunlight given the 2024-2025 benzene findings - not a reason to stop it, just a storage precaution.

For PIH after inflammatory acne reduces can we suggest Topical Azelaic Acid 15-20% in the night along with the current Gel Adapalene 0.1 % or they have to be separated?

Finding Sources
Finding Sources
Searching the Web

azelaic acid combined with adapalene same time irritation stability

Good question, and the answer depends on distinguishing a chemical incompatibility issue from a cumulative irritation issue.

Chemical compatibility: not a problem

Azelaic acid and adapalene do not have the kind of interaction seen with benzoyl peroxide + tretinoin (where BPO oxidizes and inactivates certain retinoids). Azelaic acid is chemically stable and is commonly formulated and used alongside retinoids in clinical practice. So there is no pharmacologic reason they must be kept on separate days or separate times of day the way BPO and some retinoids are.

Irritation load: this is the real consideration

Both agents are independently associated with subjective/sensory irritation - stinging, burning, dryness, and erythema without necessarily visible signs - and this risk is additive when applied together (Fitzpatrick's Dermatology; Dermatology, 2-Vol Set 5e, on subjective irritant contact dermatitis from azelaic acid, benzoyl peroxide, and retinoids). Your patient is already on a retinoid + BPO regimen, so stacking a third active (azelaic acid) at night on top of adapalene raises the cumulative irritant burden, particularly right as you're trying to calm inflamed, PIH-prone skin.

Practical recommendation

You don't need to separate them to AM/PM - continue BPO in the morning and use the night slot for both azelaic acid and adapalene - but sequence and pace them rather than combining at full strength immediately:
  1. Cleanse with a gentle, non-comedogenic cleanser and let skin dry fully (~10-15 minutes) before applying anything - reduces stinging.
  2. Apply azelaic acid 15-20% first, wait about 10-15 minutes for absorption, then apply adapalene 0.1% over it. (Applying the potentially more irritating/thinner retinoid last, over an already-absorbed base layer, tends to minimize stinging; some clinicians reverse the order - either works, consistency matters more than the exact order.)
  3. Titrate rather than starting nightly-combined from day one, especially since you're adding a new active to an already-active regimen:
    • Week 1-2: azelaic acid on alternate nights only (e.g., Mon/Wed/Fri), adapalene alone on the other nights.
    • Week 3-4: if well tolerated, move to nightly co-application as above.
  4. Moisturize after both actives absorb (non-comedogenic, ceramide-based) if any dryness or flaking appears.
  5. Continue the morning sunscreen you already have him on - both azelaic acid and adapalene (and his doxycycline) increase photosensitivity/UV vulnerability, and this also directly protects against worsening the PIH you're trying to treat.
  6. If stinging, marked redness, or peeling occurs, drop back to alternate nights or the "azelaic acid one night, adapalene the next" pattern rather than pushing through - poor tolerability is the main reason this combination fails, not lack of efficacy.
Once his active inflammatory lesions and PIH have both substantially improved (typically 8-12 weeks of consistent use, since azelaic acid's depigmenting effect is gradual), he can drop back to a simpler maintenance regimen (retinoid ± BPO), reintroducing azelaic acid intermittently if PIH recurs.

Create a step-by-step treatment protocol document for this patient's care plan

Reading File
Running Command

mkdir -p /tmp/workspace/acne-protocol && ls -la /tmp/workspace/

Writing File

~/acne-protocol/build_doc.py

from docx import Document
from docx.shared import Pt, Inches, RGBColor
from docx.enum.text import WD_ALIGN_PARAGRAPH
from docx.enum.table import WD_TABLE_ALIGNMENT
from docx.oxml.ns import qn
from docx.oxml import OxmlElement

DARK = RGBColor(0x1F, 0x3B, 0x57)
ACCENT = RGBColor(0x2E, 0x74, 0xB5)
GREY = RGBColor(0x59, 0x59, 0x59)

doc = Document()

# Default style
style = doc.styles["Normal"]
style.font.name = "Calibri"
style.font.size = Pt(11)

# Margins
for section in doc.sections:
    section.top_margin = Inches(0.7)
    section.bottom_margin = Inches(0.7)
    section.left_margin = Inches(0.8)
    section.right_margin = Inches(0.8)

def shade_cell(cell, hex_color):
    tcPr = cell._tc.get_or_add_tcPr()
    shd = OxmlElement('w:shd')
    shd.set(qn('w:val'), 'clear')
    shd.set(qn('w:color'), 'auto')
    shd.set(qn('w:fill'), hex_color)
    tcPr.append(shd)

def set_col_widths(table, widths):
    for row in table.rows:
        for idx, w in enumerate(widths):
            row.cells[idx].width = w

def add_heading(text, level=1, color=DARK):
    h = doc.add_heading(text, level=level)
    for run in h.runs:
        run.font.color.rgb = color
    return h

def add_body(text, bold=False, italic=False, size=11, color=None, space_after=6):
    p = doc.add_paragraph()
    p.paragraph_format.space_after = Pt(space_after)
    run = p.add_run(text)
    run.bold = bold
    run.italic = italic
    run.font.size = Pt(size)
    if color:
        run.font.color.rgb = color
    return p

def add_bullet(text, bold_lead=None):
    p = doc.add_paragraph(style="List Bullet")
    if bold_lead:
        r = p.add_run(bold_lead)
        r.bold = True
        p.add_run(text)
    else:
        p.add_run(text)
    return p

def add_numbered(text, bold_lead=None):
    p = doc.add_paragraph(style="List Number")
    if bold_lead:
        r = p.add_run(bold_lead)
        r.bold = True
        p.add_run(text)
    else:
        p.add_run(text)
    return p

# ---------------- TITLE PAGE / HEADER ----------------
title = doc.add_paragraph()
title.alignment = WD_ALIGN_PARAGRAPH.CENTER
run = title.add_run("ACNE VULGARIS TREATMENT PROTOCOL")
run.bold = True
run.font.size = Pt(22)
run.font.color.rgb = DARK

subtitle = doc.add_paragraph()
subtitle.alignment = WD_ALIGN_PARAGRAPH.CENTER
run = subtitle.add_run("Individualized Step-by-Step Care Plan — Nodular Acne with Post-Inflammatory Hyperpigmentation (PIH)")
run.italic = True
run.font.size = Pt(13)
run.font.color.rgb = ACCENT

doc.add_paragraph()

# Patient summary box (table)
table = doc.add_table(rows=6, cols=2)
table.style = "Light Grid Accent 1"
data = [
    ("Patient", "28-year-old male"),
    ("Diagnosis", "Mild nodular acne (few, consistently nodular lesions), jaw-predominant, with post-inflammatory hyperpigmentation (PIH)"),
    ("Regimen duration to date", "6-7 weeks"),
    ("Current medications", "Tab. Doxycycline 100 mg OD (AM); Gel Benzoyl Peroxide 5% (AM); Gel Adapalene 0.1% (PM)"),
    ("Protocol basis", "AAD 2024 Guidelines of Care for Acne Vulgaris (Reynolds et al., JAAD 2024; PMID 38300170); 2025 Oral Antibiotic Stewardship Consensus; NICE/BAD guidance"),
    ("Document prepared", "Clinical reference protocol — for treating clinician's use and patient counseling"),
]
for i, (k, v) in enumerate(data):
    c0, c1 = table.rows[i].cells
    c0.text = ""
    p0 = c0.paragraphs[0]
    r0 = p0.add_run(k)
    r0.bold = True
    r0.font.size = Pt(10.5)
    shade_cell(c0, "DCE6F1")
    c1.text = ""
    p1 = c1.paragraphs[0]
    r1 = p1.add_run(v)
    r1.font.size = Pt(10.5)
set_col_widths(table, [Inches(1.6), Inches(4.9)])

doc.add_paragraph()

# ---------------- STEP 0: GOALS ----------------
add_heading("Protocol Goals", level=1)
add_bullet("Clear active inflammatory/nodular lesions while minimizing further scarring and PIH.")
add_bullet("Practice antibiotic stewardship — cap oral doxycycline duration and transition to topical maintenance.")
add_bullet("Actively treat existing PIH once acne inflammation is controlled.")
add_bullet("Minimize cumulative irritation from combined topical actives through sequencing and pacing.")
add_bullet("Define explicit escalation criteria (isotretinoin referral) if the current approach fails.")

# ---------------- STEP-BY-STEP PROTOCOL ----------------
add_heading("Step-by-Step Care Plan", level=1)

# STEP 1
add_heading("Step 1 (Weeks 0-2, i.e., NOW) — Continue Induction Therapy + Close Gaps", level=2, color=ACCENT)
add_numbered("Continue Tab. Doxycycline 100 mg once daily (morning) — do not stop yet; response typically takes 6-8 weeks.")
add_numbered("Continue Gel Benzoyl Peroxide 5% every morning — apply to entire acne-prone area, not spot treatment.")
add_numbered("Continue Gel Adapalene 0.1% every night.")
add_numbered("ADD: Broad-spectrum, non-comedogenic sunscreen (SPF 30-50) every morning — mandatory given doxycycline photosensitivity and to prevent worsening of PIH.")
add_numbered("Doxycycline administration counseling: take with a full glass of water; remain upright ≥30 minutes afterward; separate from dairy, calcium, iron, or antacids by ~2 hours.")
add_numbered("Storage counseling for benzoyl peroxide: store at room temperature, away from heat and direct sunlight (per 2024-2025 FDA/Valisure benzene-degradation findings) — continue use, this is a precaution, not a reason to stop.")
add_numbered("If dryness/irritation occurs from adapalene + BPO, use a non-comedogenic, fragrance-free moisturizer; do not discontinue actives for mild dryness alone.")

# STEP 2
add_heading("Step 2 (Weeks 2-4) — Nodule-Directed Adjunct", level=2, color=ACCENT)
add_numbered("For the persistent nodular lesion(s): consider intralesional triamcinolone acetonide 2.5-5 mg/mL injected directly into each nodule.", bold_lead="Intralesional therapy: ")
add_numbered("This accelerates flattening of individual nodules and reduces the risk of scarring/further PIH — appropriate for \"few but consistently nodular\" lesions, per AAD 2024 good practice statement on adjuvant intralesional corticosteroids.")
add_numbered("Continue all Step 1 measures unchanged.")
add_numbered("Reinforce adherence: ask specifically how many nights per week the patient actually applies each topical.")

# STEP 3
add_heading("Step 3 (Once active inflammatory lesions are visibly reducing) — Introduce PIH-Directed Therapy", level=2, color=ACCENT)
add_numbered("Do not add azelaic acid while acne is still highly active/inflamed and skin is not yet tolerating adapalene + BPO comfortably — wait until inflammation is subsiding.")
add_numbered("Continue Gel Benzoyl Peroxide 5% each morning + sunscreen.", bold_lead="Morning: ")
add_numbered("Cleanse with a gentle, non-comedogenic cleanser; allow skin to dry fully (10-15 minutes) before applying any active.", bold_lead="Night — new sequenced routine: ")
add_numbered("Apply Azelaic Acid 15-20% first; wait ~10-15 minutes for absorption.")
add_numbered("Then apply Gel Adapalene 0.1% over it.")
add_numbered("Follow with a non-comedogenic moisturizer if any dryness/stinging is noted.")
p = add_body("Note on compatibility: ", bold=True, space_after=0)
p.add_run("Azelaic acid and adapalene are chemically compatible (unlike benzoyl peroxide + certain retinoids, which can oxidize/inactivate each other) — they do NOT need to be separated to different times of day. The concern is cumulative irritation, not chemical interaction, hence the graded introduction below.")

add_heading("Step 3a — Graded Introduction Schedule (to minimize irritation)", level=3, color=GREY)
tbl2 = doc.add_table(rows=4, cols=3)
tbl2.style = "Light List Accent 1"
hdr = tbl2.rows[0].cells
for i, txt in enumerate(["Timeframe", "Azelaic Acid 15-20%", "Adapalene 0.1%"]):
    hdr[i].text = ""
    r = hdr[i].paragraphs[0].add_run(txt)
    r.bold = True
    shade_cell(hdr[i], "2E74B5")
    r.font.color.rgb = RGBColor(0xFF, 0xFF, 0xFF)
rows_data = [
    ("Week 1-2", "Alternate nights only (e.g., Mon/Wed/Fri)", "Nights azelaic acid is NOT applied"),
    ("Week 3-4", "If tolerated, move to nightly", "Nightly, applied after azelaic acid absorbs"),
    ("If stinging/redness/peeling occurs", "Drop back to alternate-night pattern or pause 2-3 nights", "Same — reduce frequency together, resume gradually"),
]
for i, row in enumerate(rows_data, start=1):
    for j, val in enumerate(row):
        tbl2.rows[i].cells[j].text = val

# STEP 4
add_heading("Step 4 (Week 12 / 3 months) — Antibiotic Stop Point and Reassessment", level=2, color=ACCENT)
add_numbered("Formal reassessment of lesion count, nodule status, and PIH extent.")
add_numbered("Per AAD 2024 and the 2025 antibiotic stewardship consensus, oral doxycycline should not exceed 3-4 months.", bold_lead="Stop oral doxycycline: ")
add_numbered("Continue Gel Adapalene 0.1% (or fixed-dose adapalene/BPO combination product) as long-term maintenance to prevent relapse.", bold_lead="Transition to topical-only maintenance: ")
add_numbered("Continue benzoyl peroxide morning +/- azelaic acid as needed for residual PIH.")
add_numbered("Continue daily sunscreen indefinitely.")

# STEP 5 - Decision branch
add_heading("Step 5 — Decision Branch at 12-Week Reassessment", level=2, color=ACCENT)

tbl3 = doc.add_table(rows=3, cols=2)
tbl3.style = "Light Grid Accent 1"
hdr3 = tbl3.rows[0].cells
for i, txt in enumerate(["Clinical Finding", "Action"]):
    hdr3[i].text = ""
    r = hdr3[i].paragraphs[0].add_run(txt)
    r.bold = True
    shade_cell(hdr3[i], "1F3B57")
    r.font.color.rgb = RGBColor(0xFF, 0xFF, 0xFF)
branch_data = [
    ("Good response: nodules resolved, no new nodules, PIH fading",
     "Stop doxycycline; continue topical maintenance (adapalene + BPO ± azelaic acid) indefinitely; routine follow-up in 3 months."),
    ("Inadequate response: new nodules forming, scarring appearing, or recurrent nodular flares despite optimized combination therapy",
     "Refer for oral isotretinoin evaluation, per AAD 2024 strong recommendation for acne that is severe, scarring, or failing standard oral/topical therapy. Obtain baseline LFTs and lipid panel before initiation."),
]
for i, (finding, action) in enumerate(branch_data, start=1):
    tbl3.rows[i].cells[0].text = finding
    tbl3.rows[i].cells[1].text = action

doc.add_paragraph()

# ---------------- MONITORING TABLE ----------------
add_heading("Monitoring Schedule", level=1)
tbl4 = doc.add_table(rows=5, cols=3)
tbl4.style = "Light Grid Accent 1"
hdr4 = tbl4.rows[0].cells
for i, txt in enumerate(["Visit / Timepoint", "What to Assess", "Action if Needed"]):
    hdr4[i].text = ""
    r = hdr4[i].paragraphs[0].add_run(txt)
    r.bold = True
    shade_cell(hdr4[i], "2E74B5")
    r.font.color.rgb = RGBColor(0xFF, 0xFF, 0xFF)
mon_data = [
    ("Week 6-8 (baseline / current)", "Lesion count, nodule status, tolerability of adapalene+BPO, adherence", "Add sunscreen; consider intralesional triamcinolone for nodules"),
    ("Week 8-10", "Inflammation trend, readiness to start PIH-directed therapy", "Introduce azelaic acid on graded schedule if inflammation subsiding"),
    ("Week 12 (antibiotic stop point)", "Overall response, nodule recurrence, PIH extent, side effects", "Stop doxycycline; shift to topical maintenance or escalate to isotretinoin referral per decision branch"),
    ("Every 3 months thereafter", "Maintenance adherence, relapse, residual PIH", "Adjust topical regimen; taper azelaic acid once PIH resolves"),
]
for i, row in enumerate(mon_data, start=1):
    for j, val in enumerate(row):
        tbl4.rows[i].cells[j].text = val

doc.add_paragraph()

# ---------------- PATIENT COUNSELING POINTS ----------------
add_heading("Patient Counseling Checklist", level=1)
add_bullet("Improvement is gradual — expect visible change only after 6-8 weeks of consistent use.")
add_bullet("Apply topical medications to the entire acne-prone area, not just individual spots.")
add_bullet("Avoid picking or manipulating nodules — this worsens scarring and PIH.")
add_bullet("Avoid harsh scrubs, toners, or additional over-the-counter actives not part of this plan.")
add_bullet("Use sunscreen every morning without exception — protects against doxycycline photosensitivity and prevents PIH from darkening further.")
add_bullet("Report any persistent stinging, burning, or peeling promptly so the regimen can be adjusted rather than abandoned.")

doc.add_paragraph()

# ---------------- REFERENCES ----------------
add_heading("Guideline Basis / References", level=1)
refs = [
    "Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of Care for the Management of Acne Vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-1006.e30. PMID: 38300170.",
    "Optimal Use Recommendations and Stewardship Principles with Oral Antibiotics in Acne Vulgaris Management: An Expert Consensus Panel (2025).",
    "NICE Guideline NG198 - Acne Vulgaris: Management (2023), with 2024 practice update (Layton AM, et al. Dermatol Ther. 2024).",
    "Dermatology, 2-Volume Set, 5th Edition (Elsevier) - Chapter on Acne Vulgaris and Postinflammatory Hyperpigmentation.",
    "Fitzpatrick's Dermatology, editors' volumes 1-2 - Sections on Retinoids, Azelaic Acid, and Tetracycline Photosensitivity.",
    "FDA Drug Alert: Limited Voluntary Recalls After Testing of Acne Products for Benzene (March 2025).",
]
for r in refs:
    add_bullet(r)

doc.add_paragraph()
foot = doc.add_paragraph()
foot.alignment = WD_ALIGN_PARAGRAPH.CENTER
r = foot.add_run("This protocol is a clinical decision-support reference and does not replace individualized clinical judgment or in-person evaluation.")
r.italic = True
r.font.size = Pt(9)
r.font.color.rgb = GREY

doc.save("/tmp/workspace/acne-protocol/Acne_Treatment_Protocol.docx")
print("Saved.")
Running Command

cd /tmp/workspace/acne-protocol && python3 build_doc.py

Running Command

cd /tmp/workspace/acne-protocol && python3 -c " from docx import Document doc = Document('Acne_Treatment_Protocol.docx') count_p = len(doc.paragraphs) count_t = len(doc.tables) print('paragraphs:', count_p, 'tables:', count_t) " && ls -la /tmp/workspace/acne-protocol/

Document created successfully. Here's the deliverable:

Acne Treatment Protocol

Word Document · DOCX

What's inside:
  • Patient summary table - diagnosis, current regimen, duration, guideline basis
  • Protocol goals - clearing lesions, antibiotic stewardship, PIH treatment, minimizing irritation, defined escalation criteria
  • 5-step chronological care plan:
    1. Weeks 0-2 (now) - continue induction therapy, add sunscreen, doxycycline/BPO administration counseling
    2. Weeks 2-4 - intralesional triamcinolone for the nodules
    3. Once inflammation subsides - introduce azelaic acid with the sequenced night routine and a graded alternate-night-to-nightly build-up table (to manage irritation, not chemical incompatibility)
    4. Week 12 - hard stop on doxycycline, transition to topical maintenance
    5. Decision branch table - continue maintenance vs. refer for isotretinoin, based on response
  • Monitoring schedule table tied to each visit
  • Patient counseling checklist
  • Guideline references (AAD 2024, NICE, antibiotic stewardship consensus, FDA benzene alert, textbook sources)
This consolidates everything discussed across the conversation into a single actionable, dated protocol your clinical team or the patient's chart can follow step by step. Let me know if you'd like a simplified one-page patient handout version as well.
This is a shared conversation. Sign in to Orris to start your own chat.